万拉法新与多虑平治疗焦虑症对照研究

A controlled study between venlafaxine and doxepin in the treatment of anxiety

目的 比较万拉法新与多虑平治疗焦虑症的疗效与副反应。方法 将 6 8例符合CCMD - 3诊断标准的焦虑症患者 ,随机分为万拉法新治疗 (A)组 34例 ,多虑平治疗 (B)组 34例 ,共治疗 6w。于治疗前及治疗第 2、4、6w末 ,采用HAMA、SAS和TESS评价临床疗效与副反应。结果 万拉法新组治疗 1w后HAMA、SAS评分与治疗前比较有非常显著性差异 (P <0 .0 1;多虑平组治疗 2w后HAMA、SAS评分与治疗前比较有非常显著性差异 (P <0 .0 1;两组间比较除第 1w末有显著性差异 (P <0 .0 5外 ,2、4、6w末差异无显著性 (P >0 .0 5 ) ;万拉法新组副反应明显少于多虑平组 ,两组比较差异有显著性 (P <0 .0 1)。结论 万拉法新治疗焦虑症安全。

Objective To compare the efficacy and side effects between venlafaxine and doxepin in the treatment of anxiety. Methods 68 patients with anxiety(met the criterion of CCMD-3 for anxiety) were randomly divided into group A(n=34,venlafaxine) and B(n=34,doxepin) for 6 weeks, efficacy and side effects assessed by HAMA,SAS and TESS before and at the ends of 2nd,4th and 6th week during treatment. Results After one week treatment, scores of HAMA and SAS showed significant difference from pre-treatment(P<0.01) in group A; after two week treatment, scores of HAMA and SAS showed significant difference from pre-treatment(P<0.01) in group B; comparison of the 2 groups showed significant difference at end of 1st week(P<0.01) and no significant difference at ends of 2nd,4th and 6th week(P>0.05);side effects of group A were fewer than that of group B, comparison of the 2 groups showed significant difference(P<0.01).Conclusion Venlafaxine is safe and effective in the treatment of anxiety.